<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11367">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00579813</url>
  </required_header>
  <id_info>
    <org_study_id>32677</org_study_id>
    <secondary_id>NIH grant R01DK071277</secondary_id>
    <nct_id>NCT00579813</nct_id>
  </id_info>
  <brief_title>Mechanisms Underlying Metabolic Syndrome in Obesity</brief_title>
  <official_title>Mechanisms Underlying Metabolic Syndrome in Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to better understand the link between obesity and diabetes or
      pre-diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity is the most common and powerful force for creating insulin resistance and metabolic
      syndrome, however, the molecular basis of this association is not well understood. In this
      proposal, three independently funded researchers—Philip Kern, MD a clinical investigator,
      and Charlotte Peterson, PhD and Robert McGehee, PhD, with significant experience in muscle
      and adipocyte biology, respectively—will formalize a collaborative effort as a natural
      extension of previous work and shared interests in the fields of obesity, insulin
      resistance, and tissue lipid accumulation. Our overall hypothesis is that insulin resistance
      in humans stems largely from ectopic accumulation of intramyocellular lipid (IMCL) during
      the development of obesity. Further, we hypothesize that excess IMCL accumulation is
      dependent on secretory proteins derived from a complex interplay between adipocytes and
      macrophages in adipose tissue. To test these hypotheses, we will examine the interactions
      among adipocytes, macrophages, and muscle cells isolated and cultured from subjects that are
      obese with insulin resistance and impaired glucose tolerance (IGT), and from some with Type
      2 Diabetes. This study population has elevated IMCL and is at high risk for obesity
      complications, but avoids the pathophysiologic complications of glucotoxicity. These
      subjects will be compared to obese subjects with normal glucose tolerance (NGT).

      Aim 1 will explore mechanisms that contribute to IMCL and elucidate its role in the
      development of IGT. Cultured muscle cells will be used to determine whether obese subjects
      with IGT versus NGT demonstrate intrinsic differences in muscle gene expression and
      metabolic activity under differing extracellular fatty acid concentrations. Lipid
      accumulation and oxidation, and insulin-mediated glycogen synthesis and signaling will be
      assessed.

      Aim 2 will determine if the IMCL accumulation is dependent on adipose tissue secretory
      proteins. We will use co-cultures of adipocytes, myoblasts, and adipose stromal vascular
      cells to examine IMCL and the development of insulin resistance.

      Aim 3 will determine whether the stromal fraction from IGT subjects promotes IMCL more
      effectively than that from NGT subjects in co-cultures with muscle cells. We will compare
      the stromal vascular fractions with regard to monocyte/macrophage accumulation and cytokine
      expression.

      Aim 4 will determine if improved glucose tolerance in response to a 10-week treatment with
      pioglitazone results in decreased IMCL and identify cellular mechanisms involved. Co-culture
      studies will also be used with muscle and stromal cells, before and after pioglitazone
      treatment. These experiments will provide mechanistic insight into the link between obesity
      and muscle function leading to metabolic syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Particpants</measure>
    <time_frame>December 2009</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Insulin Resistance</condition>
  <condition>Prediabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Baseline studies (OGTT, DXA, RMR, FSIGT, and biopsies) on normal control subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Baseline studies (OGTT, DXA, RMR, FSIGT, biopsies), then 10 weeks treatment on Pioglitazone. Baseline tests are repeated at the end of medication treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Pioglitazone 30mg for 2 weeks, then Pioglitazone 45mg for 8 weeks.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 years of age

          -  BMI 28+

          -  diabetes, impaired glucose tolerance or normal glucose tolerance

        Exclusion Criteria:

          -  AST &gt;2x normal

          -  congestive heart failure

          -  history of coronary artery disease

          -  chronic renal insufficiency (creatinine &gt; 1.4mg/dl)

          -  use of gemfibrozil, ACE inhibitors, and angiotensin receptor II blockers, or
             anticoagulants
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert E McGehee, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <lastchanged_date>August 22, 2011</lastchanged_date>
  <firstreceived_date>December 20, 2007</firstreceived_date>
  <firstreceived_results_date>February 22, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>inflammation</keyword>
  <keyword>diabetes</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lean Subjects</title>
          <description>Arm 1 was normal subjects on which baseline studies were performed to determine insulin sensitivity, intramyocellular lipid and resting metabolic rate.</description>
        </group>
        <group group_id="P2">
          <title>Obese Subjects</title>
          <description>Baseline studies (Oral glucose tolerance test, Dual energy x-ray absorbiometry, Resting metabolic rate, Frequently sampled intravenous glucose tolerance test, biopsies), then 10 weeks treatment on Pioglitazone. Baseline tests are repeated at the end of medication treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lean Subjects</title>
          <description>Arm 1 was normal subjects on which baseline studies were performed to determine insulin sensitivity, intramyocellular lipid and resting metabolic rate.</description>
        </group>
        <group group_id="B2">
          <title>Obese Subjects</title>
          <description>Baseline studies (Oral glucose tolerance test, Dual energy x-ray absorbiometry, Resting metabolic rate, Frequently sampled intravenous glucose tolerance test, biopsies), then 10 weeks treatment on Pioglitazone. Baseline tests are repeated at the end of medication treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="70"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="70"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="53" spread="6"/>
                <measurement group_id="B2" value="57" spread="2"/>
                <measurement group_id="B3" value="55" spread="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="45"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="52"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="18"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="70"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Particpants</title>
        <time_frame>December 2009</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Lean Subjects</title>
            <description>Arm 1 was normal subjects on which baseline studies were performed to determine insulin sensitivity, intramyocellular lipid and resting metabolic rate.</description>
          </group>
          <group group_id="O2">
            <title>Obese Subjects</title>
            <description>Baseline studies (Oral glucose tolerance test, Dual energy x-ray absorbiometry, Resting metabolic rate, Frequently sampled intravenous glucose tolerance test, biopsies), then 10 weeks treatment on Pioglitazone. Baseline tests are repeated at the end of medication treatment.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Particpants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Glucose Tolerance of Normal Subjects</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lean Subjects</title>
          <description>Arm 1 was normal subjects on which baseline studies were performed to determine insulin sensitivity, intramyocellular lipid and resting metabolic rate.</description>
        </group>
        <group group_id="E2">
          <title>Obese Subjects</title>
          <description>Baseline studies (Oral glucose tolerance test, Dual energy x-ray absorbiometry, Resting metabolic rate, Frequently sampled intravenous glucose tolerance test, biopsies), then 10 weeks treatment on Pioglitazone. Baseline tests are repeated at the end of medication treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert E. McGehee Jr., Ph.D.</name_or_title>
      <organization>University of Arkansas for Medical Sciences</organization>
      <phone>501-603-1998</phone>
      <email>rem@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
